Ross G Hewitt

Summary

Affiliation: University at Buffalo
Country: USA

Publications

  1. ncbi Abacavir hypersensitivity reaction
    Ross G Hewitt
    Departments of Medicine and Pharmacy Practice, State University of New York, Buffalo, NY, 14215, USA
    Clin Infect Dis 34:1137-42. 2002
  2. ncbi New-onset seizures as an initial presentation of end-stage renal failure in patients with HIV/AIDS
    Toyin F Olatinwo
    State University of New York at Buffalo, USA
    AIDS Read 12:269-75. 2002
  3. ncbi Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients
    Mark J Shelton
    Laboratory for Antiviral Research, Department of Pharmacy Practice, University at Buffalo, New York, USA
    Antimicrob Agents Chemother 47:1694-9. 2003
  4. ncbi Effects of didanosine formulations on the pharmacokinetics of amprenavir
    Mark J Shelton
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709-3398, USA
    Pharmacotherapy 23:835-42. 2003

Collaborators

  • Gene Morse
  • Mark J Shelton
  • Toyin F Olatinwo
  • John Adams
  • Charles S Berenson
  • Andrew Della-Coletta
  • Denise Cloen
  • Angela A Giovanniello
  • Robin DiFrancesco
  • Steven Cox
  • Kim Keil

Detail Information

Publications4

  1. ncbi Abacavir hypersensitivity reaction
    Ross G Hewitt
    Departments of Medicine and Pharmacy Practice, State University of New York, Buffalo, NY, 14215, USA
    Clin Infect Dis 34:1137-42. 2002
    ..Clinical management involves supportive measures and discontinuation of abacavir therapy. Rechallenge with abacavir in a hypersensitive patient should be avoided because it might precipitate a life-threatening reaction...
  2. ncbi New-onset seizures as an initial presentation of end-stage renal failure in patients with HIV/AIDS
    Toyin F Olatinwo
    State University of New York at Buffalo, USA
    AIDS Read 12:269-75. 2002
    ..Seizures tended to be recurrent, sometimes despite anticonvulsant therapy. In a subset of patients, seizures were the initial presenting sign of HIV infection...
  3. ncbi Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients
    Mark J Shelton
    Laboratory for Antiviral Research, Department of Pharmacy Practice, University at Buffalo, New York, USA
    Antimicrob Agents Chemother 47:1694-9. 2003
    ..h, and a C(min) of 9.1 +/- 7.5 micro M. Therefore, delavirdine increases systemic exposure to ritonavir by 50 to 80% when the drugs are coadministered...
  4. ncbi Effects of didanosine formulations on the pharmacokinetics of amprenavir
    Mark J Shelton
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709-3398, USA
    Pharmacotherapy 23:835-42. 2003
    ..Therefore, amprenavir may be administered concurrently with either the buffered or the encapsulated enteric-coated bead formulation of didanosine in the fasting state...